|
|
|
|
In 2025, the clinical trial industry is under pressure to enhance return on investment and streamline operations. Point-of-need care models have emerged as a vital strategy to address persistent challenges such as recruitment bottlenecks, retention issues, and rising costs.
|
|
|
|
|
Explore the key components of new FDA guidance on decentralized clinical trials, including the use of Mobile Research Units (MRUs) to facilitate local healthcare provider involvement and minimize participant burden through reduced travel and administrative demands.
|
|
|
|
|
Ophthalmic clinical trials are integral to advancing treatments for vision-threatening conditions, but their inherent complexity presents challenges. By embracing point-of-need models and strategic collaborations, sponsors and CROs can streamline ophthalmic trials, enhance efficiency, and maximize ROI while advancing sight-saving therapies.
|
|
|
|
|
As the link between ocular health and central nervous system (CNS) conditions like Alzheimer's and Multiple Sclerosis becomes clearer, biopharmaceutical companies are increasingly incorporating these insights into their clinical trial designs. Learn more about the innovative approach being taken by 20/20 Onsite to facilitate this pairing.
|
|
|
|
|
The aging population in the U.S. is driving an increased demand for specialty eye care, yet a significant shortage of ophthalmologists poses a challenge for clinical trials. Mobile clinics are becoming crucial to addressing these issues, offering on-site eye assessments, improving trial efficiency, and enhancing patient experiences.
|
|
|
|
|
Comprehensive ophthalmology assessments are vital in clinical trials for ensuring treatment safety and efficacy. However, several overlooked hurdles complicate their implementation at clinical sites, particularly those without specialized resources.
|
|
|
|
|
|
|
